Two Sigma Advisers
ARQT icon

Two Sigma Advisers’s Arcutis Biotherapeutics ARQT Stock Holding History

Two Sigma Advisers’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-156,100
Closed -$4.53M – 168
2025
Q4 		$4.53M Buy
156,100
+141,000
+934% +$3.61M 0.01% 854
2025
Q3 		$285K Sell
15,100
-600
-4% -$9.46K ﹤0.01% 2009
2025
Q2 		$220K Sell
15,700
-55,100
-78% -$772K ﹤0.01% 2087
2025
Q1 		$1.11M Buy
+70,800
New +$997K ﹤0.01% 1429
2024
Q4 		– Sell
-182,800
Closed -$1.7M – 2337
2024
Q3 		$1.7M Sell
182,800
-305,800
-63% -$3.02M ﹤0.01% 1156
2024
Q2 		$4.54M Buy
488,600
+157,700
+48% +$1.43M 0.01% 801
2024
Q1 		$3.28M Buy
+330,900
New +$2.47M 0.01% 961
2023
Q2 		– Sell
-16,000
Closed -$176K – 2381
2023
Q1 		$176K Sell
16,000
-119,600
-88% -$1.73M ﹤0.01% 2287
2022
Q4 		$2.01M Buy
135,600
+64,400
+90% +$1.13M 0.01% 1249
2022
Q3 		$1.36M Buy
+71,200
New +$1.61M ﹤0.01% 1373
2021
Q4 		– Sell
-27,700
Closed -$662K – 2614
2021
Q3 		$662K Sell
27,700
-34,200
-55% -$780K ﹤0.01% 1806
2021
Q2 		$1.69M Sell
61,900
-15,700
-20% -$442K ﹤0.01% 1376
2021
Q1 		$2.25M Buy
77,600
+48,300
+165% +$1.51M 0.01% 1207
2020
Q4 		$824K Buy
+29,300
New +$718K ﹤0.01% 1659

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Advisers's ARQT Position: Q1 2026 in Review

Two Sigma Advisers sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 156,100 shares — an estimated $4.53M sold.

Two Sigma Advisers first reported a position in ARQT in Q4 2020 and held it in 14 quarters. The position peaked at $4.54M in Q2 2024. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Two Sigma Advisers reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 156,100 Arcutis Biotherapeutics shares in Q1 2026, an estimated $4.53M.
  • Two Sigma Advisers first reported a position in Arcutis Biotherapeutics in Q4 2020 and held it in 14 quarters.
  • Two Sigma Advisers's Arcutis Biotherapeutics position peaked at $4.54M in Q2 2024.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.